Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

282 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia.
Loriaux MM, Levine RL, Tyner JW, Fröhling S, Scholl C, Stoffregen EP, Wernig G, Erickson H, Eide CA, Berger R, Bernard OA, Griffin JD, Stone RM, Lee B, Meyerson M, Heinrich MC, Deininger MW, Gilliland DG, Druker BJ. Loriaux MM, et al. Among authors: heinrich mc. Blood. 2008 May 1;111(9):4788-96. doi: 10.1182/blood-2007-07-101394. Epub 2008 Feb 5. Blood. 2008. PMID: 18252861 Free PMC article.
Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases.
Heinrich MC, Joensuu H, Demetri GD, Corless CL, Apperley J, Fletcher JA, Soulieres D, Dirnhofer S, Harlow A, Town A, McKinley A, Supple SG, Seymour J, Di Scala L, van Oosterom A, Herrmann R, Nikolova Z, McArthur AG; Imatinib Target Exploration Consortium Study B2225. Heinrich MC, et al. Clin Cancer Res. 2008 May 1;14(9):2717-25. doi: 10.1158/1078-0432.CCR-07-4575. Clin Cancer Res. 2008. PMID: 18451237 Clinical Trial.
An activating KRAS mutation in imatinib-resistant chronic myeloid leukemia.
Agarwal A, Eide CA, Harlow A, Corbin AS, Mauro MJ, Druker BJ, Corless CL, Heinrich MC, Deininger MW. Agarwal A, et al. Among authors: heinrich mc. Leukemia. 2008 Dec;22(12):2269-72. doi: 10.1038/leu.2008.124. Epub 2008 May 29. Leukemia. 2008. PMID: 18509354 No abstract available.
Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.
Heinrich MC, Maki RG, Corless CL, Antonescu CR, Harlow A, Griffith D, Town A, McKinley A, Ou WB, Fletcher JA, Fletcher CD, Huang X, Cohen DP, Baum CM, Demetri GD. Heinrich MC, et al. J Clin Oncol. 2008 Nov 20;26(33):5352-9. doi: 10.1200/JCO.2007.15.7461. Epub 2008 Oct 27. J Clin Oncol. 2008. PMID: 18955458 Free PMC article. Clinical Trial.
Molecular determinants of response to matuzumab in combination with paclitaxel for patients with advanced non-small cell lung cancer.
Schittenhelm MM, Kollmannsberger C, Oechsle K, Harlow A, Morich J, Honecker F, Kurek R, Störkel S, Kanz L, Corless CL, Wong KK, Bokemeyer C, Heinrich MC. Schittenhelm MM, et al. Among authors: heinrich mc. Mol Cancer Ther. 2009 Mar;8(3):481-9. doi: 10.1158/1535-7163.MCT-08-1068. Epub 2009 Mar 10. Mol Cancer Ther. 2009. PMID: 19276157
Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registry.
Beadling C, Heinrich MC, Warrick A, Forbes EM, Nelson D, Justusson E, Levine J, Neff TL, Patterson J, Presnell A, McKinley A, Winter LJ, Dewey C, Harlow A, Barney O, Druker BJ, Schuff KG, Corless CL. Beadling C, et al. Among authors: heinrich mc. J Mol Diagn. 2011 Sep;13(5):504-13. doi: 10.1016/j.jmoldx.2011.04.003. Epub 2011 Jul 2. J Mol Diagn. 2011. PMID: 21726664 Free PMC article.
282 results